Thomas Salzmann
Plus aucun poste en cours
Profil
Dr. Salzmann sits on the Board and SAB of Satori Pharmaceuticals, a PureTech portfolio company.
Previously he was Executive Vice President, Merck Research Labs.
Dr. Salzmann's career at Merck spanned nearly 30 years in which he has also held positions including EVP Worldwide Preclinical Development, Global Operations, and Project Management and SVP Basic Research and Chemistry.
He is also a member of the MRL Executive Committee.
Anciens postes connus de Thomas Salzmann
| Sociétés | Poste | Fin |
|---|---|---|
Puretech Health LLC
 Puretech Health LLC Investment ManagersFinance Puretech Health LLC (PureTech Ventures) is a venture capital subsidiary of PureTech Health Plc founded in 2000 by Daphne Zohar, Robert Langer and Ben Shapiro. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 30/07/2008 |
Satori Pharmaceuticals, Inc.
 Satori Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satori Pharmaceuticals, Inc. developed therapeutics for alzheimer's disease. The firm's drug candidates selectively modulated gamma secretase, the enzyme generating the neurotoxic peptides that form amyloid beta plaques the signature of this debilitated disease. The company was founded by Mark A. Findeis and Dennis J. Selkoe in 2005 and was headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Puretech Health LLC
Puretech Health LLC Investment ManagersFinance Puretech Health LLC (PureTech Ventures) is a venture capital subsidiary of PureTech Health Plc founded in 2000 by Daphne Zohar, Robert Langer and Ben Shapiro. The firm is headquartered in Boston, Massachusetts. | Finance |
Satori Pharmaceuticals, Inc.
Satori Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satori Pharmaceuticals, Inc. developed therapeutics for alzheimer's disease. The firm's drug candidates selectively modulated gamma secretase, the enzyme generating the neurotoxic peptides that form amyloid beta plaques the signature of this debilitated disease. The company was founded by Mark A. Findeis and Dennis J. Selkoe in 2005 and was headquartered in Cambridge, MA. | Health Technology |
